Role of tors as de-escalation strategy in hpv-related oropharyngeal cancer, what we need to know

HIGHLIGHTS

• What: The ongoing ADEPT trial investigates reduced-dose adjuvant RT and the study aims to compare standard adjuvant chemoradiotherapy (CRT) with a reduced dose of adjuvant RT in HPV-positive OPSCC patients. The aim of this scoping review is to discuss the challenges of risk stratification the importance of status determination and the implications of smoking on treatment outcomes. The trial showed promising results, with a 2-year locoregional tumor control rate of 96.2%, a progression-free survival rate of 91.1%, and an overall survival rate of 98.7%. This study showed that 92% of . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.